To find details of topics the National Institute for Health and Care Excellence has been invited to consider for technology appraisal please:

We used to include details of topics being scoped for technology appraisal on this page. No further topics will be added.

Jump to:

 

 

Inhaled alpha-1 antitrypsin for treating emphysema

Suggested remit

To appraise the clinical and cost effectiveness of inhaled alpha-1 antitrypsin within its marketing authorisation for treating emphysema.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

24 May 2017 – 22 June 2017

 

Batch

55

 

ID number

1200

 

Scoping workshop

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of inhaled alpha-1 antitrypsin for treating emphysema ID1200 We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal.

The company that develop Inhaled alpha-1 antitrypsin have advised NICE that they have withdrawn their marketing authorisation application for this product for this indication and plan to resubmit their application in few years after collecting additional data from a planned phase 3 study. In light of this information, the Institute will not be progressing with the scoping exercise. Consequently, the scoping workshop arranged for Friday 14 July 2017 has been cancelled.

If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on 44 (0)20 7045 2239 or via email on michelle.adhemar@nice.org.uk.

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Exploratory work of bevacizumab in eye conditions

Background

In 2010 the Department of Health asked NICE to explore with stakeholders what value NICE can add in advising the NHS on the clinical and cost effectiveness of Avastin (bevacizumab) to treat wet age-related macular degeneration, the leading cause of blindness in the UK, and other conditions affecting the eye.

 

Consultation on briefing document and provisional list of stakeholders

02 June 2010 – 30 June 2010

 
 

Exploratory workshop

13 July 2010 in Manchester

 

Back to top